Pharmacogenomics Testing - MEDICAID - FLORIDA

This policy covers pharmacogenomic genotype testing for DPYD (CPT 81232) to guide dosing of fluoropyrimidine therapies (e.g., capecitabine, 5‑FU) and NUDT15 (81306) and TPMT (84433) genotyping to guide thiopurine dosing, when performed before therapy initiation or to evaluate severe/unexpected toxicity. Coverage is limited to these specific CPT-coded tests and indications for eligible plan members, many multi-gene/commercial panels and other listed pharmacogenomic tests are not covered, and the policy cites limited supporting evidence for broader pharmacogenomic testing.

"Genomind Pharmacogenetics Report - Full (0423U) — Not eligible / Not covered"

Sign up to see full coverage criteria, indications, and limitations.